Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H29N3O.2ClH |
Molecular Weight | 436.418 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OCCN1CCN(CCCN2C3=C(C=CC=C3)C=CC4=C2C=CC=C4)CC1
InChI
InChIKey=DLTOEESOSYKJBK-UHFFFAOYSA-N
InChI=1S/C23H29N3O.2ClH/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26;;/h1-4,6-11,27H,5,12-19H2;2*1H
DescriptionSources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25722522
Sources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25722522
Opipramol (Insidon, Pramolan, Ensidon, Oprimol) is an antidepressant and anxiolytic used in Germany and other European countries. Although it is a member of the tricyclic antidepressants, opipramol's primary mechanism of action is much different in comparison, it doesn’t represent a tricyclic antidepressant drug as it does not inhibit the neuronal uptake of norepinephrine and/or serotonin. Opipramol also acts as a low to moderate affinity antagonist for the D2, 5-HT2, H1, H2, and muscarinic acetylcholine receptors. H1 and H2 receptor antagonism account for its antihistamine effects, and muscarinic acetylcholine receptor antagonism is responsible for its anticholinergic properties. Opipramol was developed by Schindler and Blattner in 1961. Opipramol is typically used in the treatment of generalized anxiety disorder (GAD) and somatoform disorders. Its anxiolysis becomes prominent after only one to two weeks of chronic administration. Upon first commencing treatment, opipramol is rather sedating in nature due to its antihistamine properties, but this effect becomes less prominent with time. The therapy with Opipramol indicates an additional therapy with neuroleptics, hypnotics and tranquilizers (e.g. Barbiturates, Benzodiazepines). Therefore, it should be noted that some specific reactions, particularly CNS depressant effects could be intensified and an intensification of common side effects may occur. If necessary the dosage may be reduced. Co-administration with alcohol can cause stupor. MAO Inhibitors should be discontinued at least 14 days before the treatment with Opipramol. Concomitant use of Opipramol with β-blockers, antiarrhythmics (of class 1c), as well as drugs from tricyclic antidepressant group and preparations which influence the microsomal enzyme system, can lead to change in plasma concentration of these drugs. Co-administration of neuroleptics (example- haloperidol, risperidone) can increase the plasma concentration.
Originator
Sources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdf
Curator's Comment: 1961
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11199949 |
|||
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25722522 |
|||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25722522 |
|||
Target ID: CHEMBL2095200 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25722522 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Some central effects of opipramol given repeatedly. | 1990 Sep-Oct |
|
Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. | 2001 Feb |
|
Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. | 2003 Dec |
|
Specific modulation of sigma binding sites by the anxiolytic drug opipramol. | 2003 Oct |
|
[Somatoform disorders--what must the general practitioner know?]. | 2004 Aug 19 |
|
Urine sample preparation of tricyclic antidepressants by means of a supported liquid membrane technique for high-performance liquid chromatographic analysis. | 2004 Mar 5 |
|
Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. | 2004 Nov |
|
Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. | 2005 Oct |
|
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression. | 2006 |
|
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
A retrospective analysis of antidepressant poisonings in the emergency department: 11-year experience. | 2006 Oct |
|
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. | 2006 Oct 20 |
|
Generalised anxiety disorder. | 2007 Nov 20 |
|
Frequency of different anti-depressants associated with suicides and drug deaths. | 2008 Mar |
|
Gastroprotective and antioxidant effects of opipramol on indomethacin-induced ulcers in rats. | 2009 Jul |
|
Opipramol as nighttime medication. | 2009 May |
|
Determination of the chemical structure of potential organic impurities occurring in the drug substance opipramol. | 2010 Apr |
|
Opipramol dipicrate. | 2010 Jul 10 |
|
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. | 2010 Nov |
|
Tricyclic antidepressants and headaches: systematic review and meta-analysis. | 2010 Oct 20 |
|
Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. | 2010 Oct 7 |
|
In vitro studies of DNA damage caused by tricyclic antidepressants: a role of peroxidase in the side effects of the drugs. | 2010 Sep 20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://medind.nic.in/daa/t13/i2/daat13i2p409.pdf
50 mg in morning; 50 mg in the afternoon and 100 mg in the evening
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5045752
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
C87667
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
71587
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
m8218
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
213-000-2
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
82062
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL370753
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
100000092384
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
909-39-7
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
SUB03520MIG
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY | |||
|
B49OBI656M
Created by
admin on Fri Dec 15 15:10:30 GMT 2023 , Edited by admin on Fri Dec 15 15:10:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD